Summit Therapeutics Inc. SMMT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 248.47M | 306.11M | 603.76M | 556.75M | 493.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 855.24M | 874.84M | 1.22B | 1.09B | 935.11M |
| Operating Income | -855.24M | -874.84M | -1.22B | -1.09B | -935.11M |
| Income Before Tax | -832.68M | -856.09M | -1.21B | -1.08B | -921.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -832.68 | -856.09 | -1.21K | -1.08K | -921.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -832.68M | -856.09M | -1.21B | -1.08B | -921.62M |
| EBIT | -855.24M | -874.84M | -1.22B | -1.09B | -935.11M |
| EBITDA | -855.03M | -874.67M | -1.22B | -1.09B | -934.99M |
| EPS Basic | -1.07 | -1.12 | -1.60 | -1.44 | -1.24 |
| Normalized Basic EPS | -0.67 | -0.70 | -1.00 | -0.90 | -0.78 |
| EPS Diluted | -1.07 | -1.12 | -1.60 | -1.45 | -1.25 |
| Normalized Diluted EPS | -0.67 | -0.70 | -1.00 | -0.90 | -0.78 |
| Average Basic Shares Outstanding | 3.12B | 3.06B | 3.03B | 2.99B | 2.96B |
| Average Diluted Shares Outstanding | 3.12B | 3.06B | 3.03B | 2.99B | 2.96B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |